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Aims: Endothelin ETB receptors mediate under normal physiological conditions vasorelaxation in coronary arteries.
However, vasocontractile ETB receptors appear in coronary arteries of ischemic heart disease patients. Interestingly,
organ culture of isolated coronary arteries also induces upregulation of vasocontractile ETB receptors. This study ex-
amines the early time course and mechanism behind upregulation of contractile ETB receptors in isolated rat coro-
nary arteries during short-term organ culture.
Main methods: Coronary artery segments were mounted in wire-myographs and incubated in physiological saline
solution. Contractions were measured after exposure to the speciﬁc ETB receptor agonist Sarafotoxin 6c (S6c) and
the endogenous agonists endothelin-1 and endothelin-3. Protein localization and levels of ETB and phosphorylated-
extracellular-signal-regulated-kinase-1/2 (ERK1/2) were examined by immunohistochemistry.
Key ﬁndings: Fresh arteries showed negligible vasoconstriction to S6c. However, incubation for only 4 and 7 h in-
creased S6c contractions two- and seven-fold, respectively. Furthermore, 7 h incubation enhanced vasocontractile
responses to endothelin-3 and increasedETB receptor density in vascular smoothmuscle cells. ERK1/2was activat-
ed rapidly after start of incubation.Moreover, incubationwith either the transcriptional inhibitor actinomycinD or
the mitogen-activated-protein kinase kinase 1/2 (MEK1/2) inhibitor U0126 attenuated contractile ETB receptor
upregulation. U0126 attenuated ETB receptor protein levels after 24 h of incubation.
Signiﬁcance: Coronary arteries rapidly upregulate vasocontractile ETB receptors during organ culture via transcrip-
tional mechanisms and MEK-ERK1/2 signalling. This model may mimic the mechanisms seen in ischemic condi-
tions. Furthermore, these ﬁndings have important experimental implications in tissue bath experiments lasting
for more than 4 h.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
The endothelin family of vasoactive peptides consists of endothelin-1
(ET-1), -2 (ET-2), and -3 (ET-3). The endothelins mediate their effects
through two distinct G-protein coupled receptor subtypes, ETA and ETB
(Arai et al. 1990a; Sakurai et al. 1990; Yanagisawa et al. 1988). Under nor-
mal physiological conditions ETA is the dominant endothelin receptor
subtype expressed in vascular smoothmuscle cells (VSMC),where itme-
diates strong vasoconstriction (Adner et al. 1998b;Wang et al. 1998). ETB
receptors are under normal conditions mainly expressed on endothelial
cells where they mediate vasodilatation via production and release of
nitric oxide (Hirata et al. 1993) and prostacyclin (Filep et al. 1991). How-
ever, in several pathophysiological conditions ETB receptors are upregu-
lated in VSMC where they mediate vasoconstriction. Upregulation ofperimental Research, Glostrup
Hospital, Ndr. Ringvej 69, DK-
293; fax: +45 38633983.
.
Y-NC-ND license.ETB receptors in VSMC of coronary arteries has been demonstrated in ex-
perimental congestive heart failure (Cannan et al. 1996) and in patients
with ischemic heart disease (Wackenfors et al. 2004; Dagassan et al.
1996a). In addition, forearm blood ﬂow studies have revealed increased
ETB receptor-dependent vasoconstriction in patientswith atherosclerosis
as compared to controls (Pernow et al. 2000).
Upregulation of contractile ETB receptors in VSMC has also been
demonstrated to take place in a variety of arteries during in vitro
organ culture in serum-free culture medium. In left coronary arteries
(LAD), it has been demonstrated that the stimulation of fresh human,
rat and porcine arteries with the ETB-speciﬁc agonist S6c gives no or
only a weak vasocontractile response, whereas a strong contractile
ETB receptor-mediated response appears after 1–2 day of organ cul-
ture in serum-free Dulbecco's Modiﬁed Eagles Medium (DMEM)
(Johnsson et al. 2008; Nilsson et al. 2008). Information about ETB re-
ceptor plasticity in other parts of the coronary arterial tree is lacking.
Themolecular mechanisms underlying VSMC ETB receptor upregula-
tion have been studied after 24–48 h organ culture in both coronary and
cerebral arteries. The increased expression of contractile ETB receptor at
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nisms and PKC and the extracellular signal-regulated kinases 1 and 2
(ERK1/2) have been identiﬁed as upstream mediators of the increased
ETB receptor gene expression (Henriksson et al. 2004; Nilsson et al.
2008; Sandhu et al. 2010). However, the detailed time course of the
ETB receptor upregulation in rat coronary arteries at time points earlier
than 24 h after start of organ culture has hitherto not been studied.
Moreover, it is not clear from the earlier reports whether the critical fac-
tor triggering the ETB receptor upregulation during organ culture of cor-
onary arteries is serum-deprivation or low oxygen tension, both of
which are prominent characteristics of the DMEM in vitro organ culture
model hitherto used.
Consequently, the aimof the present studywas to investigatewheth-
er an ETB receptor-mediated vasoconstrictor response developed during
short-term incubation of isolated LAD as well as septal coronary artery
(SCA) segments in oxygenated buffer in a myograph. Furthermore, we
aimed at investigating the detailed time course and molecular mecha-
nisms behind this putative early ETB receptor plasticity.
Materials and methods
Animals and isolated vessel preparation
Male Sprague–Dawley rats (Taconic, Denmark) (9–12 weeks,
260–410 g) were sedated with 70% CO2 in 30% O2 and killed by de-
capitation. The heart was immediately excised and placed into ice
cold oxygenated physiological saline solution (PSS) composed of (in
mM): 119 NaCl, 4.7 KCl, 2.5 CaCl2, 25 NaHCO3, 1.17 MgSO4, 1.18
KH2PO4, 5.5 glucose, and 0.03 EDTA, pH 7.4. The LAD and the SCA
(segment length 1–2 mm) were dissected in ice cold, oxygenated PSS
and mounted on a Mulvany–Halpern wire myograph (model 610 M,
Danish Myo Technology A/S, Aarhus, Denmark). The myographs were
connected to a PowerLab Unit (ADInstruments, UK) and responses
were sampled in LabChart™ (6.0, ADInstruments). The mounted artery
segments were heated to 37 °C. After 15 min equilibration, the vessels
were stretched to their optimal lumen diameter L1=0.9×L100, where
L100 is an estimate of the diameter of the vessel under a passive trans-
mural pressure of 100 mmHg, in order to obtain optimal conditions for
active tension development. Subsequently, the vessels were allowed to
stabilize for 20–30 min. In addition, the vessels were washed every
15 minwith PSS. During incubation procedure in themyograph, the ves-
sels were kept at this standard tension. To ensure a stable pH (7.40±
0.05), all myograph baths were continuously gassed with 12% CO2 in
88% O2, pH in the myograph baths was constantly monitored with a pH
meter and gas ﬂow to each bath was carefully adjusted accordingly.
Experimental protocols
Effect of myograph incubation time on ET receptor-mediated responses
ETB receptor-mediated responses were investigated using the
peptide Sarafotoxin 6c (S6c), which exhibits high selectivity for the
ETB receptor over the ETA receptors. Four consecutive cumulative
concentration–response curves (1 pM to 30 nM) were obtained for
each arterial segment at 1½, 4, 7 or 24 h after mounting the arteries
in the myograph baths. Before each concentration–response curve,
the vascular smooth muscle cell contractile function was conﬁrmed
by challenging the segments two or three times with 125 mM K+
(KPSS, similar to PSS except that NaCl was exchanged for KCl on an equi-
molar basis). Dual ETA and ETB-mediated responses were investigated
using the endogenous ligands, ET-1 (1 pM to 30 nM) and ET-3 (1 pM to
0.3 μM). Because ET-1 produces a long-lasting vasocontractile response,
it was only possible to perform one concentration–response curve on
each arterial segment. Cumulative ET-1 and ET-3 concentration–response
curves were accomplished at either 1½ or 7 h of incubation in the myo-
graphbath in apairedparallel experimental set-up. The effect of the selec-
tive ETA receptor antagonist BQ123 (10 μM) on the ET-1 response wasevaluated by adding the antagonist 30 min before ET-1 concentration–
response curves after either 1½ or 7 h of incubation.
Effect of prolonged exposure to U0126 and actinomycin D
Vessel segments were incubated in PSS buffer for 7 h with either
the MEK1/2 inhibitor U0126 (10 μM), the transcription inhibitor acti-
nomycin D (4 μM) or equal volumes of vehicle DMSO and subse-
quently S6c concentration–contraction curves were recorded.
Acute effect of U0126
Vessel segments were incubated in PSS buffer for 7 h. The
mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor U0126
(10 μM) or equal volumes of vehicle DMSO was added 30 min before
onset of recording of S6c concentration–contraction curves.
Endothelium function and maximal contractile capacity
Endothelium function was determined on all artery segments by
assessing the relaxation to the acetylcholine receptor agonist carba-
chol (10 μM) after obtaining steady-state pre-contraction tone with
prostaglandin F2α (PGF2α) (10 μM). Endothelial function at 100%
was deﬁned as a carbachol induced relaxation to baseline of the
PGF2α induced contraction. Maximal relaxationwas determined by ex-
posing the vessels to calcium-free buffer solution (Ca2+-free PSS) buffer.
After the third concentration–response curve, the arteries maximal con-
tractile capacity of the arterieswas assessed by addition of a cocktail solu-
tion (KPSS with 10 μM PGF2α and 10 μM 5-hydroxytryptamine (5-HT))
(Fig. 1 supplementary material). Maximal contractile capacities were cal-
culated as the difference between maximal tension induced by cocktail
solution andmaximal relaxation induced by Ca2+-free PSS. All contractile
responses are expressed as percentage of the maximal contraction in-
duced by cocktail solution. Emax represents the maximum contractile re-
sponse elicited by an agonist, and EC50 (as negative logarithm: pEC50)
represents the agonist concentration eliciting 50% of the maximum re-
sponse. Basal vascular tone was determined as the difference between
tension of vessels when kept in PSS and calcium-free PSS. Only segments
with a basal tone b35% of the maximal contractility were included.
Immunohistochemistry
Rat coronary arteries were isolated and incubated for ½, 1½, 4, 7
or 24 h in oxygenated PSS buffer containing either U0126 (10 μM)
or equal volumes of vehicle DMSO. The immunostaining protocol is
described in details in supplementary materials. In short, the vessels
were snap-frozen in Tissue TEK® (Gibco) and sectioned with a thick-
ness of 10 μm on a cryostat. Following ﬁxation, permeabilization, and
blocking, the sections were incubated with primary antibodies to
actin (mouse anti-actin, 1:500, Abcam, UK) and to either ETB recep-
tors (sheep anti-ETB receptor, 1:250, Alexis Biochemicals, UK) or
phosphorylated ERK1/2 (rabbit anti-phosphor-p44/42 MAPK, 1:200,
Cell Signaling, USA). The following secondary antibodies were used:
donkey anti-mouse dylight™ 549, donkey anti-sheep dylight™ 488,
and donkey anti-rabbit dylight™ 488 (all from Jackson ImmunoRe-
search, UK (1:200)). Immunoreactivity was visualized and photo-
graphed with a Nikon confocal microscope (EZ-c1, Germany) at the
appropriate wavelengths.
Data analyses
Data were analysed using GraphPad Prism© software (GraphPad
Software Inc., USA) and are expressed as mean±SEM (n equals the
number of animals). All contractile responses from the in vitro phar-
macology experiments are expressed as percentage of the maximal
contraction induced by cocktail solution (KCl, 125 mM, PGF2α.
0.01 mM, and serotonin 0.01 mM). Emax represents the maximum
contractile response elicited by an agonist and EC50 (as negative log-
arithm: pEC50) represents the agonist concentration required to
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peated measurements and Bonferroni multiple comparisons post-
test were used to compare concentration–response curves obtained
in coronary arteries. .Student's t-test (for paired or unpaired groups
as appropriate) was used on experiment comparing only two mean
values. One-way ANOVA Bonferroni multiple comparisons post-test
was used to compare signiﬁcant differences between immunoreactiv-
ity results. All statistical analyses were considered signiﬁcant when
pb0.05.
Chemicals
All drugs and chemicals for myograph studies were acquired from
Sigma-Aldrich unless otherwise indicated. ET-1 and S6c were obtained
from NeoMPS (Strassbourg, France). Actinomycin D, U0126, and BQ788
were prepared as stock solutions in DMSO in concentrations of 10 mM,
20 mM, and 1.8 mM, respectively. S6c and ET-1 were dissolved in 0.1%
BSA in distilled water to reach stock concentrations at 0.1 mM. PBS tab-
lets (Invitrogen) was dissolved in distilled water reaching following
concentrations: 0.14 M NaCl, 0.01 M PO4 buffer, 0.003 M KCl.
Results
The average diameters of LAD segments (340±16 μm) were larg-
er than those of SCA segments (260±13 μm). However, maximal
contractile capacity (KPSS with 10 μM PGF2α and 10 μM 5-HT) was
not signiﬁcantly different between LAD (6.4±0.8 mN/mm) and SCA
(7.0±0.5 mN/mm) segments. In most experiments, LAD had a slight-
ly higher basal tone compared to SCA, and since the basal tone in LAD
was highly dependent on the pH in the buffer, the pH was kept tightly
in a range between 7.35 and 7.45.
Time course of contractile ETB receptor upregulation
To investigate the time course of incubation-induced upregulation
of contractile ETB receptors, we investigated contractile responses to
the ETB-speciﬁc agonist S6c after various time periods of incubation.
S6c-mediated contraction was negligible after 1½ h incubation of
LAD and SCA (Emax=9.5±3.8% and 6.3±4.4% of maximal contrac-
tion, respectively), but the response successively increased with
time. The S6c-induced contraction increased by approximately two-
fold after 4 h incubation in both LAD (Emax 20.1±4.5%, p>0.05) and
SCA (11.3±4.6%, p>0.05), and by approximately seven-fold after 7 h
of incubation (LAD Emax=68.6±4.2% and SCA Emax=45.4±5.2%,
pb0.001) (Fig. 1A and B). The response increased only slightly further
after 24 h of incubation in LAD and SCA. There was no change in pEC50
over time despite the successive increases in Emax. Contractile re-
sponses to K+ (125 mM) and to the cocktail (KPSS, PGF2α and 5-HT)
were not signiﬁcantly altered at the time points studied (supplementa-
ry data). The S6c-induced concentration–response curves recorded after
7 h incubation were unaffected by whether the vessels had been stimu-
latedwith S6c in previous concentration–response curves or just incubat-
ed without stimulation, indicating that incubation-induced upregulation
of the contractile ETB response is not affected by stimulation of the ETB re-
ceptors with S6c during the incubation.
To investigate the importance of the enhanced ETB-mediated con-
tractility for the contractile responses to endogenous endothelin re-
ceptor agonists, we determined ET-1 and ET-3-induced contractile
responses before or after incubation for 7 h. The contractile response
to ET-1 was unchanged by incubation for 7 h in both LAD and SCA
(Fig. 1B and E). In contrast, 7 h incubation resulted in a leftwards
shifted of ET-3 concentration–response curve in both LAD and SCA.
This was more pronounced in LAD, in which the pEC50 shifted from
7.2±0.03 to 9.7±0.7 compared to SCA, where pEC50 shifted from
6.3±0.3 to 7.5±0.1 (Fig. 1C and F).In order to ascertain whether the observed development of an ETB
receptor-mediated contractile response was an indirect effect of dis-
turbed endothelium-mediated vasodilatation in the arterial segments
during incubation, the presence of intact functional endothelium in
the arteries was tested by precontracting the arteries with PGF2α
(10 μM) and subsequently induce endothelium-mediated vasodilata-
tion by application of carbachol (10 μM). There was no signiﬁcant dif-
ference between endothelium-mediated relaxation in LAD (53±8%)
and SCA (62±7%). Furthermore, there was no correlation between
endothelium function and S6c-induced vasoconstriction after 7 h in-
cubation in neither LAD nor SCA (supplementary data), indicating
that the observed enhanced ETB receptor-mediated contractility is
not dependent on changes in endothelium function.
Involvement of contractile ETB receptors in ET-1 induced contraction
The speciﬁc competitive ETA receptor antagonist BQ123 (10 μM)
was added 30 min before recording of ET-1 concentration–response
curves at either 1½ h or 7 h of incubation. BQ123 induced a parallel
and rightward shift of the ET-1 concentration–response curve in
both coronary artery segments after 1½ h of incubation (LAD
pEC50=8.9±0.1 and SCA pEC50=8.5±0.1 without BQ123, and LAD
pEC50=8.3±0.3 and SCA pEC50=7.6±1.5 with BQ123) without sig-
niﬁcant alteration in the maximal contractile responses (Fig. 2A and
D). This indicates that after 1½ h of incubation the ET-1 induced con-
traction is mediated by ETA receptors. In SCA BQ123 induced a parallel
rightward shift of ET-1 concentration–response curve after 7 h of in-
cubation (Fig. 2E). In contrast in LAD after 7 h of incubation an ETA re-
ceptor blocking resulted in a biphasic ET-1 concentration–response
curve (Fig. 2B). These results indicate that, although the shape of
ET-1 induced contraction–response curve does not change after incu-
bation (Fig. 1B), the ET-1 induced contraction after 7 h of incubation
involves both ETA and ETB receptor in LAD.
Involvement of gene transcription and MEK1/2 activity in upregulation
of contractile ETB receptor
The increase in S6c induced contraction during 7 h incubation was
inhibited by incubation in the presence of either the transcriptional
inhibitor actinomycin D (4 μM) or the MEK1/2 inhibitor U0126
(10 μM) (Fig. 2C and F). Segments incubated with vehicle for 7 h
showed Emax of 56.7±2.2% and 51.7±3.6% in LAD and SCA, respec-
tively. Segments incubated for 7 h in the presence of actinomycin D
displayed signiﬁcantly reduced Emax values at 27.2±5.3% (LAD) and
15.2±6.5% (SCA). Segments incubated for 7 h in the presence of
U0126 also showed signiﬁcantly reduced Emax values at 32.9±6.0%
(LAD) and 16.7±3.9% (SCA). These ﬁndings indicate that both tran-
scriptional mechanisms and intracellular signalling via MEK1/2 is in-
volved in the upregulation of contractile ETB receptors.
In order to determine whether U0126 (10 μM) had a direct attenu-
ating effect on S6c-induced contraction, the MEK1/2 inhibitor was
added 30 min before S6c concentration–response curves were obtained
(after 7 h incubation). U0126 did not affect the S6c induced contraction
compared to control segments, which had been given an equal volume
DMSO (data not shown), indicating that the above described effect of
7 h incubation in the presence of U0126 is not the result of an acute ef-
fect of U0126 on ETB-mediated contraction.
Immunohistochemistry
Speciﬁc antibodies towards the ETB receptor visualised the pro-
teins localized in VSMC after incubation (Fig. 3A). The ETB receptor
protein expression increased signiﬁcantly after 7 h (208±29%,
pb0.05) and 24 h incubation (385±54%, pb0.001) as compared to
non-incubated arteries (100±14%).
Fig. 1. Log concentration–response curves to Sarafotoxin 6c (S6c) in rat (A) LAD (n=4–14) and (D) SCA (n=3–14). Log concentration–response curves to endothelin-1 (ET-1) in
rat (B) LAD (n=9–11) and (E) SCA (n=9–10). Log concentration–response curves to endothelin-3 (ET-3) in rat (C) LAD (n=6) and (F) SCA (n=6). The experiments were per-
formed after 1½ (circles), 4 (squares), 7 (triangles), and 24 (cross) h of incubation in PSS buffer. Values plotted as means±SEM. (*** pb0.001, ** pb0.01,*pb0.05), time of incu-
bation vs. 1½ h, two-way ANOVA with repeated measurements and Bonferroni multiple comparisons test were used.
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increased ETB receptor expression, we examined the effect of the se-
lective MEK1/2 inhibitor U0126. Incubation with U0126 (10 μM) sig-
niﬁcantly attenuated ETB receptor expression after 24 h incubation
(198±12%, pb0.05) compared to segments incubated for 24 h in
the presence of the DMSO (385±54%) (Fig. 3A). U0126 had no signif-
icant effect on the increased ETB receptor expression after 7 h
incubation.
To demonstrate activation of the MEK-ERK1/2 signalling pathway
during incubation, coronary arteries were incubated for 0, ½, 1½, 4, 7,
and 24 h in PSS with and without U0126 (10 μM) (Figs. 3B) and the
levels of phosphorylated ERK1/2 in the segments were determined
by immunohistochemistry. ERK1/2 phosphorylation increased signif-
icantly after 1½ h (219±40%) and 4 h incubation (404±28%) as
compared to non-incubated arteries (100±18%). After 7 h and 24 h
the level of phosphorylated ERK1/2 decreased. Incubation of the cor-
onary arteries with 10 μM U0126 signiﬁcantly abolished ERK1/2
phosphorylation at all incubation times, except for 24 h of incubation,
where the level of phosphorylated ERK1/2 was negligible.
Discussion
The present study demonstrates for the ﬁrst time that only 7 h in-
cubation of isolated coronary artery segments in oxygenated physio-
logical buffer in a myograph induces a signiﬁcant upregulation of
contractile ETB receptors. This rapid upregulation of ETB receptors is
important to keep in mind, if tissue bath experiments on coronaryarteries persist for more than 4 h, due to a potentially interference
of these emerging ETB receptors. This rapid functional upregulation
is associated with increased ETB receptor immunoreactivity in VSMC
and is abolished by the transcription inhibitor actinomycin D and
the MEK1/2 inhibitor U0126.
Mounting evidence suggests that under different pathological cir-
cumstances including atherosclerosis (Dagassan et al. 1996a; Pernow
et al. 2000), ischemic heart disease (Dimitrijevic et al. 2009;
Wackenfors et al. 2004), and focal cerebral ischemia (Stenman et al.
2002), the balance of vasoconstriction and relaxation by endothelin
receptor activation is skewed towards a contractile phenotype with
increased levels of vasoconstrictive ETB receptors in VSMCs. In vitro
organ culture of isolated artery segments (Adner et al. 1998a) induces
upregulation of contractile endothelin receptors resembling the pat-
tern seen in cardiovascular diseases (Wackenfors et al. 2004), indicat-
ing that organ culture can be used as a convenient in vitro model to
study this pathophysiological phenomenon. Previous studies have
shown that fresh isolated rat coronary arteries display negligible ETB
receptor-mediated contractions (Goodwin et al. 1999; Harrison et
al. 1992), whereas a strong ETB receptor-mediated contractile re-
sponse appears after 24 h of organ culture in serum-free DMEM
(Eskesen and Edvinsson 2006; Ghorbani et al. 2010; Johnsson et al.
2008). In the present study, we studied for the ﬁrst time the early
time course of contractile ETB receptor upregulation during incuba-
tion in aerated buffer in a myograph. We demonstrate a rapid and
strong increase in S6c mediated contractile responses in coronary ar-
teries already after 7 h of incubation, which is a considerably more
Fig. 2. Log concentration–response curves to endothelin-1 (ET-1) with and without the speciﬁc ETA receptor antagonist BQ123 (10 μM) after 1½ h of incubation in rat (A) LAD and
(D) SCA and after 7 h incubation in PSS (B) LAD and (E) SCA. The speciﬁc ETA receptor antagonist BQ123 (10 μM, n=3) was added 30 min before initiation of concentration–re-
sponse curve. Values plotted are expressed as means±SEM. The maximal contractile responses to ET-1 were signiﬁcantly attenuated after 7 h incubation in the presence of either
the transcription inhibitor, actinomycin D (4 μM) (n=5) or the MEK1/2 inhibitor U0126 (10 μM) (n=7) in both (B) LAD and (D) SCA. Values plotted are expressed as means±
SEM. (*** pb0.001, ** pb0.01,*pb0.05), treatment group vs. DMSO, two-way ANOVA with repeated measurements and Bonferroni multiple comparisons test were used.
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enteric (Moller et al. 2002) and cerebral arteries (Henriksson et al.
2003). The speciﬁc involvement of ETB receptors in the rapidly upre-
gulated contractile response in coronary arteries was conﬁrmed by
the demonstration of a strong parallel rightwards shift of the S6c con-
centration–response curves using the competitive selective ETB re-
ceptor antagonist BQ788 (Ishikawa et al. 1994).
The ETA receptor has a higher afﬁnity for endothelin-1 than the two
other agonists, with an afﬁnity order of endothelin-1>endothelin-
2>endothelin-3, while the ETB receptor exhibits similar afﬁnities for
all three isopeptides (Arai et al. 1990b; Sakurai et al. 1990). Earlier stud-
ies of the selectivity of endogenous endothelins for ETA and ETB receptor
revealed that ET-1 and ET-2 bind with equal selectivity to the ETA and
ETB receptors, whereas ET-3 is the only one of the endothelin isoforms
which distinguishes between the receptors. ET-3 has a higher selectivity
for the ETB receptor than the ETA receptor (Davenport 2002). Incubation
of coronary arteries did not change the contractile responses to ET-1,
which is in accordance with earlier studies (Wackenfors et al. 2004;
Johnsson et al. 2008). However, the speciﬁc ETA receptor antagonist
BQ123 induced parallel rightward shift of the ET-1 concentration–
response curve after 1½ h of incubation, and interestingly induced a bi-
phasic ET-1 response in LAD incubated for 7 h. This indicates that the
ETA receptor dominates the vasocontractile response to ET-1 in rat cor-
onary arteries, whereas, the ETB receptor may be involved in the ET-1
induced contraction after 7 h of incubation. Studies have shown that
atherosclerotic human coronary arteries have upregulated ETB receptor(Dagassan et al. 1996b) Based on our results, one could imagine that a
local selective blockade of ETA receptor in atherosclerotic coronary ar-
teries with upregulated ETB receptors will only displace a part of the
endothelin-1 induced contraction. Whereas, targeting both receptors
with a dual ETA/B receptor blockade could be more efﬁcient.
Interestingly, we also demonstrate for the ﬁrst time that the con-
tractile responses to ET-3 is signiﬁcantly enhanced by incubation for
7 h, which is in accordance with the selectivity of this ligand for ETB
over ETA receptor.
The enhanced contractile responses to S6c after 24 h organ culture
of both cerebral and mesenteric arteries has been shown to be the re-
sult of a transcriptional upregulation of ETB receptors with increased
ETB receptor mRNA levels (Moller et al. 2002; Henriksson et al.
2003) and increased ETB receptor protein after organ culture
(Johnsson et al. 2008). In the present study, we likewise demonstrat-
ed by immunohistochemistry that ETB receptor protein levels were
increased after 7 and 24 h of incubation of the coronary arteries. In
order to investigate if the rapid upregulation of contractile ETB recep-
tors in coronary arteries during 7 h incubation occurs via transcrip-
tional mechanisms, we studied the effects of the transcriptional
inhibitor actinomycin D on S6c-induced contractions after 7 h incuba-
tion. Actinomycin D abolished the functional ETB receptor upregula-
tion after 7 h incubation in both LAD and SCA. Interestingly, the
inhibitor was not able to completely reverse the ETB receptor-
mediated response to the levels observed in fresh segments, indicat-
ing that the increased ETB receptor activity after 7 h incubation is
Fig. 3. Quantiﬁcations and montages of immunohistochemistry intensities of ETB receptors (A) and pERK (B) in the smooth muscle cell layer of LAD before culture, 0 h, after culture
(0.5 h, 1.5 h, 4 h), 7 h and 24 h and in the presence of U0126 (10 μM) or an equal volume DMSO using confocal microscopy. Note the almost complete inhibition of pERK1/2 ﬂuo-
rescent intensity, using U0126. The staining intensities are expressed as a ratio of intensity before culture=100% (mean±SEM). Number of animals in the staining n=4–6. One
Way ANOVA with Newman-Keuls multiple comparison test (** pb0.01, *** pb0.001) and Student's t-test. (# pb0.05) were used.
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involve other mechanisms as well.
ERK1/2 has previously been shown to be an upstream mediator of
ETB receptor upregulation in cerebral and mesenteric arteries
(Henriksson et al. 2004; Uddman et al. 2003). In the present study,
the level of phosphorylated ERK1/2 increased very early during the
incubation and peaked after 4 h of incubation. Incubation with the
MEK1/2 inhibitor U0126 (10 μM) completely abolished the phos-
phorylation of ERK1/2, decreased the S6c-mediated vasoconstriction
after 7 h incubation, and signiﬁcantly decreased ETB receptor protein
expression after 24 h incubation. Together; these ﬁndings strongly
suggest that signalling via the MEK-ERK1/2 pathway is involved in
functional ETB receptor upregulation during organ culture of coronary
arteries. However, since the S6c-mediated vasoconstriction after 7 h
incubation was not completely abolished in presence of U0126, this
initial functional upregulation might involve additional mechanisms.
Studies have shown that even fresh coronary arteries from healthy
rats contain ETB receptor protein in VSMC (Wendel-Wellner et al.
2002; Wendel et al. 2005). Hence, we speculate that a part of the con-
tractile ETB receptor upregulation may involve post-translational
modiﬁcations of already expressed ETB receptors.
Conclusion
In conclusion, our results demonstrate that incubation of both LAD
and SCA rat coronary arteries rapidly increases the ETB receptor-mediated
contraction as well as upregulation of ETB receptor protein levels. These
ﬁndingsmay have important experimental implications in tissue bath ex-
periments lasting for more than 4 h, due to the possible interference of
emerging ETB receptors. We demonstrate involvement of transcriptional
mechanisms andERK1/2 activity in the ETB receptor upregulationprocess.
By using the speciﬁc MEK1/2 inhibitor U0126, the upregulation of con-
tractile ETB receptors can be prevented by treatment with inhibitors of
the central signal transduction pathways underlying the upregulation
process. The here employed organ culture model represents a modelsituation with no-ﬂow and serum starvation as seen in ischemic condi-
tions. Thus, despite the obvious simplicity of themodel system, our results
suggest that ERK1/2-mediatedupregulation of vascular contractile ETB re-
ceptors may play a pivotal role in the pathogenesis of ischemic heart dis-
eases, and that inhibition of the underlying signal transduction may be a
therapeutic strategy to avoid this pathological response of the coronary
vasculature.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.lfs.2012.02.009.
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